An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In vitro transcription (IVT) is a DNA-templated process for synthesizing long RNA transcripts, including messenger RNA (mRNA). For many research and commercial applications, IVT of mRNA is typically performed using bacteriophage T7 RNA polymerase (T7 RNAP) owing to its ability to produce full-length RNA transcripts with high fidelity; however, T7 RNAP can also produce immunostimulatory byproducts such as double-stranded RNA that can affect protein expression. Such byproducts require complex purification processes, using methods such as reversed-phase high-performance liquid chromatography, to yield safe and effective mRNA-based medicines. To minimize the need for downstream purification processes, we rationally and computationally engineered a double mutant of T7 RNAP that produces substantially less immunostimulatory RNA during IVT compared with wild-type T7 RNAP. The resulting mutant allows for a simplified production process with similar mRNA potency, lower immunostimulatory content and quicker manufacturing time compared with wild-type T7 RNAP. Herein, we describe the computational design and development of this improved T7 RNAP variant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The synthesis of the nontemplated “n + 1” and “n + 2” byproducts in IVT reactions has been reported previously and considered an inherent property of T7 RNAPs.18,38,39”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [18]
In the citing paper
“To that end, different studies have shown that using engineered T7 RNAPs with mutation-enhancing termination efficiency can reduce the synthesis of dsRNA byproducts during IVT, offering the possibility of considerably streamlining mRNA manufacturing processes.18,19”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [18]
In the citing paper
“Recent improvements to the T7 RNAP through site-specific mutations determined from enzyme evolution or rational design have resulted in reactions with greater mRNA translation efficiency and fewer dsRNA byproducts.18”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [18]
In the citing paper
“As stated in a previous report,18 these n + X variants are directly related to the properties of T7 RNAP.”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates
Pichlmair, A., Schulz, O., Tan, C. P., Näslund, T. I., Liljeström, P., Weber, F., & Reis e Sousa, C. (2006) · Science · doi:10.1126/science.1132998 · Cited by 2,210
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
Durbin, A. F., Wang, C., Marcotrigiano, J., & Gehrke, L. (2016) · mBio · doi:10.1128/mbio.00833-16 · Cited by 238
Cited by
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100
“dsRNA and increased the fidelity of the IVT mRNA transcripts [82].”
Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses
Camperi, J., Roper, B., Freund, E., Leylek, R., Nissenbaum, A., Galan, C., Caothien, R., Hu, Z., Ko, P., Lee, A., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04162 · Cited by 22
Metadata
- Authors
- Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J., & Rabideau, A. E.
- Venue
- Nature Biotechnology
- Published
- 2022-11-10
- Volume
- 41
- Issue
- 4
- Pages
- 560-568
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W4308766006
- Cited by
- 235
- References
- 11
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. https://app.cochat.ai/papers/10.1038/s41587-022-01525-6
- The paper
- Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J., & Rabideau, A. E. (2023). An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nature Biotechnology. https://doi.org/10.1038/s41587-022-01525-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.